Noramco is participating in the Scientific Thought Leadership program at this year’s AAPS. Dr. Wen-Chun Zhang will be presenting a Chalk Talk on the topic of “The New Era of Ultra-Pure Synthetic Cannabinoids” on Tuesday, November 6th, 2018 from 10:30 am to 10:50.
Noramco, a leader in controlled substances and cannabinoids, is adding commercial-scale capacity of dronabinol (THC) at its Athens, Georgia, United States facility. The expansion comes in response to rising demand for its highly pure cannabidiol (CBD) and dronabinol (THC) analogs of cannabis sativa.
Noramco, a global leading producer of controlled substances, including cannabinoids for the pharmaceutical industry, today announced that it has filed a provisional patent application with the US Patent and Trademark Office (USPTO) directed to its proprietary pure cannabidiol (CBD) compositions.